These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17906702)

  • 41. Prognostic features of multiple myeloma.
    San Miguel JF; García-Sanz R
    Best Pract Res Clin Haematol; 2005; 18(4):569-83. PubMed ID: 16026738
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
    Lonial S; Cavenagh J
    Br J Haematol; 2009 Jun; 145(6):681-708. PubMed ID: 19344388
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation.
    Sherman AC; Simonton S; Latif U; Plante TG; Anaissie EJ
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):12-20. PubMed ID: 19135938
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals.
    Durie BG
    Clin Lymphoma Myeloma; 2005 Nov; 6(3):181-90. PubMed ID: 16354323
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment.
    Heider U; Kaiser M; Mieth M; Lamottke B; Rademacher J; Jakob C; Braendle E; Stover D; Sezer O
    Eur J Haematol; 2009 Jan; 82(1):31-8. PubMed ID: 19067746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In pursuit of the allo-immune response in multiple myeloma: where do we go from here?
    Cook G; Bird JM; Marks DI
    Bone Marrow Transplant; 2009 Jan; 43(2):91-9. PubMed ID: 19079310
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
    Miceli T; Colson K; Gavino M; Lilleby K;
    Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):13-20. PubMed ID: 18490253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
    El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M
    Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
    Kumar SK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
    Bone Marrow Transplant; 2008 Jun; 41(12):1013-9. PubMed ID: 18332915
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
    Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiple myeloma.
    Singhal S; Mehta J
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1322-30. PubMed ID: 17699365
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
    Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.
    Kröger N; Badbaran A; Lioznov M; Schwarz S; Zeschke S; Hildebrand Y; Ayuk F; Atanackovic D; Schilling G; Zabelina T; Bacher U; Klyuchnikov E; Shimoni A; Nagler A; Corradini P; Fehse B; Zander A
    Exp Hematol; 2009 Jul; 37(7):791-8. PubMed ID: 19487069
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation.
    Facon T; Darre S
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):737-46. PubMed ID: 18070716
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treatment with high-dose cytostatic agents].
    Wisløff F; Brinch L; Bruserud O; Dahl IM; Lamvik J
    Tidsskr Nor Laegeforen; 1994 Oct; 114(26):3115-6. PubMed ID: 7974435
    [No Abstract]   [Full Text] [Related]  

  • 57. Current therapies for multiple myeloma.
    Tariman JD
    J Infus Nurs; 2007; 30(2):113-8; quiz 121. PubMed ID: 17413496
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stem cell transplant for first relapse from the multiple myeloma research foundation.
    Anderson KC; Vesole DH
    Oncology (Williston Park); 2006 Dec; 20(14):1818, 1820-1, 1825-6. PubMed ID: 17263130
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advances in oral therapy for multiple myeloma.
    Morgan GJ; Krishnan B; Jenner M; Davies FE
    Lancet Oncol; 2006 Apr; 7(4):316-25. PubMed ID: 16574547
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In the age of novel therapies, what defines high-risk multiple myeloma?
    Badros AZ
    J Natl Compr Canc Netw; 2010 Feb; 8 Suppl 1():S28-34. PubMed ID: 20141672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.